Medtronic PLC vs Nutanix Inc — how do they compare? Medtronic PLC trades at $82.6 (market cap $106.61B), while Nutanix Inc trades at $54.33 (market cap $14.90B). The key difference: Medtronic PLC is far larger — about 7.2× Nutanix Inc's market cap, and Medtronic PLC pays a 3.46% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| MDT | NTNX | |
|---|---|---|
Market Cap | $106.61B | $14.90B |
Sector | Health | Technology |
52-Week High | $105.35 | $81.12 |
52-Week Low | $73.75 | $34.41 |
Enterprise Value | $125.36B | $14.41B |
Dividend Yield | 3.46% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Nutanix (NTNX) trades at $55.11, showing minimal daily change. The stock exhibits a bullish technical trend, supported by strong earnings beats in recent quarters, including Q1 2026 EPS of $0.47 versus $0.36 expected. Revenue growth is projected to increase from $2.54 billion in 2025 to $2.7 billion in 2026, with net income margin improving to 10.03%. Positive sentiment is fueled by recent news, such as the NVIDIA certification for its Unified Storage solution, highlighting its position in AI infrastructure.
The outlook for NTNX is positive, driven by consistent earnings outperformance and strategic positioning in hybrid multicloud and AI markets. Key opportunities include expanding profit margins and leveraging partnerships. Risks involve competitive pressures in cloud computing and reliance on enterprise spending. The consensus analyst price target of $57.80 suggests moderate upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →